Cogent Biosciences

Cogent Biosciences is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision therapies for genetically driven diseases. The company aims to discover, develop, and commercialize therapies that significantly impact patients with genetically defined conditions. By addressing the underlying causes of diseases, Cogent Biosciences seeks to restore health and improve the quality of life for patients. The company's main product is bezuclastinib, a drug candidate targeting specific mutations in the KIT receptor tyrosine kinase, primarily used for treating systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST). Cogent Biosciences also conducts clinical trials for its drug candidates and participates in scientific conferences to share its research and advancements, reflecting its commitment to innovation in the biotech field.